SIMABS is a start-up biotechnology venture that wants to develop a new bio-manufacturing platform to provide cost effective therapeutic monoclonal antibodies at small scale to biopharmaceutical companies. This technology will enable personalized medicine to become an affordable reality.
Be a center of excellence for the cost-effective biomanufacturing of monoclonal antibodies. Make batches smaller to enable biopharmaceuticals to become personalized medicine. Help governments get their healthcare budget under control and motivate pharmaceutical companies to find more innovative products.
Develop a continuous and closed manufacturing platform to produce biopharmaceuticals. Support biopharmaceutical companies in the development and manufacturing of cost effective therapeutic monoclonal antibodies. Set a new standard in biopharmaceutical manufacturing technology that enables personalized medicine to become a reality.